Form 8-K - Current report:
SEC Accession No. 0001437749-24-031268
Filing Date
2024-10-15
Accepted
2024-10-15 16:52:15
Documents
14
Period of Report
2024-10-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nrxp20241014_8k.htm   iXBRL 8-K 42544
  Complete submission text file 0001437749-24-031268.txt   194533

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nxrp-20241010.xsd EX-101.SCH 3913
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nxrp-20241010_def.xml EX-101.DEF 13475
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nxrp-20241010_lab.xml EX-101.LAB 17732
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nxrp-20241010_pre.xml EX-101.PRE 13452
16 EXTRACTED XBRL INSTANCE DOCUMENT nrxp20241014_8k_htm.xml XML 4859
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 241372419
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)